Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0LV6B
|
|||
Former ID |
DNC004552
|
|||
Drug Name |
Gly-Arg-Gly-Asp-Ser-Pro-Lys
|
|||
Synonyms |
Grgdspk; Gly-arg-gly-asp-ser-pro-lys; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, > glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C28H49N11O11
|
|||
Canonical SMILES |
C1CC(N(C1)C(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CCCN=C(N)N)NC(=O)CN)C(=O)NC(CCCCN)C(=O)O
|
|||
InChI |
1S/C28H49N11O11/c29-8-2-1-5-16(27(49)50)37-25(47)19-7-4-10-39(19)26(48)18(14-40)38-24(46)17(11-22(43)44)36-21(42)13-34-23(45)15(35-20(41)12-30)6-3-9-33-28(31)32/h15-19,40H,1-14,29-30H2,(H,34,45)(H,35,41)(H,36,42)(H,37,47)(H,38,46)(H,43,44)(H,49,50)(H4,31,32,33)/t15-,16-,17-,18-,19-/m0/s1
|
|||
InChIKey |
ZRVZOBGMZWVJOS-VMXHOPILSA-N
|
|||
CAS Number |
CAS 111119-28-9
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999 Aug 12;42(16):3033-40. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.